PCI Pharma Services and CSP Technologies, both in the US, are collaborating on the development of and clinical trials for Activ-Blister packaging, which help protect and promote speed-to-market for pharmaceutical and medical products with susceptibility to moisture and gases, especially oxygen.
Activ-Blister is designed to actively control the internal atmosphere or headspace of individual blister cavities without the use of purging, making improved stability and enhanced shelf-life possible.
Using silica-gel and molecular-sieve technology, Activ-Blister can absorb tailored amounts of moisture, oxygen and other gases, and can be produced in shapes and sizes to accommodate any tablet or capsule. The technology can be applied without changes to the existing footprints of packaging lines.
Activ-Blister can be incorporated into a wide range of blister packaging formats, including push-through blisters, peel/push blisters, cold-form foils and high barrier films containing Aclar laminates.
“Increasingly, we are seeing a need from our clients for supporting sensitive drug products,” said Bob Misher, senior vice president at PCI Clinical Services. “With the pressure on pipeline development to reduce lead-times and reduce drug development costs, coupled with a growing focus on specialised medicines, our clients are challenged to get products through clinical phases and into commercialisation more quickly than ever before. Often, this results in drug products that are very sensitive to moisture, oxygen or other gases and this can be problematic for both expedited clinical study as well as in progressing to commercialisation.”
More information from: CSP Technologies, 960 W Veterans Boulevard, Auburn, Alabama 36832, USA. Tel: 1 334 887 8300. Web: csptechnologies.com